New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
复制标题
DOI:
10.1016/j.jacc.2021.08.051
复制
发表时间:
2021-11-02
影响因子:
24
通讯作者:
Song, Wenliang
中科院分区:
文献类型:
--
作者:
Rosenson, Robert S.;Shaik, Aleesha;Song, Wenliang
关键词:
Emerging evidence suggests that elevated concentrations of triglyceride-rich lipoprotein remnants (TRLs) derived from hepatic and intestinal sources contribute to the risk of atherosclerotic cardiovascular events. Natural selection studies support a causal role for elevated concentrations of remnant cholesterol and the pathways contributing to perturbations in metabolic pathways regulating TRLs with an increased risk of atherosclerotic cardiovascular disease events. New therapies targeting select catalytic pathways in TRL metabolism reduce atherosclerosis in experimental models, and concentrations of TRLs in patients with a vast range of triglyceride levels. Clinical trials with inhibitors of angiopoietin-like 3 protein and apolipoprotein C-III will be required to provide further guidance on the potential contribution of these emerging therapies in the paradigm of cardiovascular risk management in patients with elevated remnant cholesterol.
登录
查看更多内容
影响因子:
8.1
作者:
Chi X;Britt EC;Shows HW;Hjelmaas AJ;Shetty SK;Cushing EM;Li W;Dou A;Zhang R;Davies BSJ
通讯作者:
Davies BSJ
影响因子:
39.3
作者:
Alexander, Veronica J.;Xia, Shuting;Tsimikas, Sotirios
通讯作者:
Tsimikas, Sotirios
影响因子:
24
作者:
Balling, Mie;Afzal, Shoaib;Nordestgaard, Borge G.
通讯作者:
Nordestgaard, Borge G.
影响因子:
6.5
作者:
Chen, Yan Q.;Pottanat, Thomas G.;Konrad, Robert J.
通讯作者:
Konrad, Robert J.
影响因子:
5.4
作者:
Ikezaki H;Lim E;Cupples LA;Liu CT;Asztalos BF;Schaefer EJ
通讯作者:
Schaefer EJ